Previous 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Vaxxinity (NASDAQ: VAXX) , a clinical-stage biotech, recently IPOed for a price lower than the previously announced range. In this Motley Fool Live video recorded on Nov. 15 , Motley Fool contributors Keith Speights and Brian Orelli discuss the prospects for the company's ex...
Friday’s COVID-related market selloff had a mixed impact on shares of recent IPOs – with lockdown-sensitive names like fat-removal firm AirSculpt Technologies (NASDAQ:AIRS) sinking, but biotechs like iSpecimen (NASDAQ:ISPC) and in-home fitness firms like Beachbody (NYSE:BODY) ra...
Vaxxinity (NASDAQ:VAXX) has closed its 6M-share IPO and has raised $85M in proceeds. BofA Securities, Jefferies and Evercore ISI acted as lead book-runners. Underwriters purchased an additional 537,711 shares. Vaxxinity priced its shares at $13. They closed today at $15.32. For further deta...
DALLAS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the closing of its initial public offering of 6,000,000 shares of class A common stock at a public o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rivian (NASDAQ: RIVN ) stock is taking off on Tuesday and we’re diving into all the latest news traders need to know about the company. Source: Miro Vrlik Photography / Shutterstock.com Let’s get...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, shares of Vaxxinity (NASDAQ: VAXX ) closed higher by 18% after coming public just four days ago on Nov. 11. VAXX stock debuted at $13 per share, trading as high as $22.77 on its opening day before cooling down....
Vaxxinity (VAXX +22.1%), which had its IPO on Thursday, is up another 21% today. Its IPO was priced at $13 per share. As of 205p ET today, shares were at $16.34. Vaxxinity's latest stage candidates, both in phase 2, are UB-311 for Alzheimer's disease, and UB-612 for COVID-19. For further de...
News, Short Squeeze, Breakout and More Instantly...
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological ...
BowFlex Inc. (BFXXQ) is expected to report for Q4 2024 Leafbuyer Technologies Inc (LBUY) is expected to report for Q3 2024 Pacific Booker Minerals Inc (PBMLF) is expected to report for Q1 2025 BZAM Ltd Com (BZAMF) is expected to report for Q1 2024 MJ Holdings Inc (MJNE) is expecte...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...